JGL d.d.
Svilno 20
51000 Rijeka

Security: HRJDGLO29CA5
LEI: 529900NRAH6YWL3TLD24
Home member state: Croatia
Regulated market segment: Official Market of Zagreb Stock Exchange

Rijeka, 17 November 2025

Regulated information – Change in in Executive Management, JGL d.d.

The Chief Executive Officer and member of the Management Board of JGL d.d., **Mislav Vučić**, **will complete his mandate on 30 December 2025**. Over the past eight years, through his knowledge, dedication and leadership, Mislav has achieved outstanding results and has significantly contributed to JGL's development into a successful, modern and globally recognized company.

"*I am very pleased with everything we have accomplished over these eight years – we have become the largest Croatian pharmaceutical company, tripled our sales, and created significant value for employees and shareholders. I would like to thank everyone who contributed to this shared success*", said Vučić.

To ensure the continuation of JGL's strong growth and expansion, as the new Chief Executive Officer will be appointed **Alenka Jajac-Knez**, MD, MBA, starting her mandate on 31 December 2025.

"*I am pleased that this important role will be assumed by someone from within JGL. Alenka Jajac-Knez is a proven, dedicated and capable leader who has grown and developed with the company for many years and is ready to take on the highest responsibility for our future development*", emphasized **Eva Usmiani Capobianco**, President of the Board of Directors of JGL.

As a long-standing Director of Market Operations, Jajac-Knez possesses in-depth knowledge of JGL customers' needs and the dynamics of the international market, as well as strategic insight into the company's processes. Through her expertise, experience, loyalty and personality, she has consistently delivered outstanding business results.

JGL d.d.